Breaking news

WHO’s Historic Agreement: A Major Step Towards Global Pandemic Preparedness

In a groundbreaking move, members of the World Health Organization (WHO) have reached a historic, legally binding agreement aimed at preparing the world for future pandemics. This pact, designed to address the lessons learned from the COVID-19 crisis, sets the stage for a more equitable global response to health emergencies, particularly in the distribution of essential drugs, vaccines, and medical technologies.

The agreement marks a significant milestone in global health governance, especially at a time when multilateral institutions like the WHO are facing considerable financial strain. The United States, which was once the WHO’s largest financial contributor, withdrew from negotiations after President Donald Trump initiated the U.S.’s departure from the organization. Despite this setback, the deal underscores a strong commitment from member states to work together on global health security, with or without U.S. involvement. “This is a historic moment,” said Nina Schwalbe, founder of global health think tank Spark Street Advisors. “It demonstrates that countries are committed to multilateralism and to collective action.”

This agreement, the second of its kind in WHO’s 75-year history (the first being a tobacco control treaty in 2003), focuses on structural inequalities in how pandemic-related health tools are developed and distributed. Article nine of the deal ensures that future pandemic-related drugs, therapeutics, and vaccines will be made globally accessible. It also gives the WHO stronger oversight over medical supply chains and paves the way for local production of vaccines during health crises.

A key challenge in the negotiations was the issue of technology transfer—sharing the knowledge and manufacturing capabilities necessary for lower-income countries to produce their vaccines and treatments. To address this, the agreement mandates that manufacturers allocate at least 20% of their real-time production to the WHO during a pandemic, with a minimum of 10% designated for donation and the rest priced affordably for developing nations.

The deal is not yet finalized, as it must be adopted at the WHO Assembly in May, and some details, such as the annex on Pathogen Access and Benefit Sharing, still require further negotiation. However, once ratified, the agreement will bolster global preparedness, enabling quicker responses to future pandemics and more equitable access to life-saving resources.

As health experts emphasize, the global community must invest in preparedness now to avoid the costly toll of another pandemic. “We can’t afford another pandemic, but we can afford to prevent one,” said Helen Clark, co-chair of The Independent Panel for Pandemic Preparedness. This agreement represents a critical step toward ensuring that the world is better equipped to face future health crises with solidarity, transparency, and a commitment to equity.

Ultrahuman Unveils Ring Pro As Smart Ring Competition Intensifies In The U.S.

Ultrahuman, the Bengaluru-based leader in wearable technology, has unveiled its third-generation smart ring, the Ring Pro, marking a significant step in the company’s efforts to reestablish its U.S. presence. With an extended battery life of up to 15 days and a completely redesigned form factor, the Ring Pro arrives as a strategic response following last year’s patent dispute with rival Oura.

New Design And Extended Battery Life

Ring Pro introduces a redesigned form factor alongside a dual-core processor and upgraded heart-rate sensing architecture aimed at improving data accuracy. The device is slightly heavier than its predecessor but offers enhanced on-device computing and the ability to store up to 250 days of health data. Priced at $479, the ring delivers up to 15 days of battery life, a notable increase compared to the four to six days offered by the Ring Air.

Overcoming Regulatory And Patent Hurdles

Ultrahuman’s U.S. operations faced disruption in October 2025 after the U.S. International Trade Commission ruled in favor of Oura in a patent dispute, restricting imports of new inventory. Existing stock remained available, but the decision pushed the company to redesign the product and reassess its U.S. strategy. The market remains critical for Ultrahuman, with American users accounting for roughly 45% of its 700,000 daily active users.

Introducing Jade: Real-Time Biointelligence

Alongside Ring Pro, Ultrahuman launched Jade, a real-time biointelligence system designed to provide actionable health insights instead of retrospective data summaries. According to co-founder and CEO Mohit Kumar, the system focuses on continuous analysis and real-time recommendations. Jade is available across the company’s ecosystem, including older ring models, reinforcing Ultrahuman’s AI-driven approach to wearable health monitoring.

Robust Financials And Expanding Market Influence

Despite legal and operational challenges, Ultrahuman continues to show strong financial performance. The company reports an annualized revenue run rate of approximately $150 million and operating revenue of $64 million for the fiscal year ending March 2025. Subscription services and additional offerings, including coaching programs and continuous glucose monitoring, continue to diversify revenue streams and support profitability.

Expanding Production And Global Reach

Ultrahuman is expanding production capacity as demand grows across international markets, including the UK, Canada, Australia, and India. Industry analysts note that the future of smart rings will depend on sensor precision, AI integration, and ecosystem connectivity — areas where Ultrahuman is actively investing.

With the launch of Ring Pro and the introduction of Jade, the company is aiming to strengthen its position in the fast-growing wearable technology sector while rebuilding momentum in key global markets.

Uol
eCredo
Aretilaw firm
The Future Forbes Realty Global Properties

Become a Speaker

Become a Speaker

Become a Partner

Subscribe for our weekly newsletter